Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

The Science of Rectal Microbicides Can We Make Them And Will People Use Them?

2,012 views

Published on

Ian McGowan's presentation at the AIDS 2021 satellite "Rectal Microbicides - Making HIV Prevention Gel" - July 22, 2012

Published in: Health & Medicine, Business
  • Best dissertation help you can get, thank god a friend suggested me ⇒⇒⇒WRITE-MY-PAPER.net ⇐⇐⇐ otherwise I could have never completed my dissertation on time.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • A professional Paper writing services can alleviate your stress in writing a successful paper and take the pressure off you to hand it in on time. Check out, please ⇒ www.HelpWriting.net ⇐
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Hello! I can recommend a site that has helped me. It's called ⇒ www.WritePaper.info ⇐ They helped me for writing my quality research paper.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • I pasted a website that might be helpful to you: ⇒ www.HelpWriting.net ⇐ Good luck!
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

The Science of Rectal Microbicides Can We Make Them And Will People Use Them?

  1. 1. The Science of Rectal Microbicides Can We Make Them And Will People Use Them? Ian McGowan MD PhD FRCP Magee-Womens Research Institute University of Pittsburgh
  2. 2. Microbicides are products thatcan be applied to the vaginal orrectal mucosa with the intent of preventing or significantly reducing the risk of acquiring STIs including HIV
  3. 3. How do Microbicides Work?McGowan I, Biologicals, 2006
  4. 4. Why Rectal Microbicides? Unprotected receptive anal intercourse (RAI) is the highest risk sexual activity for HIV transmission Men and women in the developed and developing world practice RAI Most people use lube for anal sex Animal studies have shown that rectal microbicides can prevent HIV infection
  5. 5. The Target Audience
  6. 6. Lube or a Rectal Microbicide?
  7. 7. OsmolalityThe concentration of a solution in terms of osmoles of solutes per kilogram of solventIso-osmolar fluids Hyperosmolar fluids (~ 300) (~ 3,000)
  8. 8. Is Lube Safe? Lubricant Osmolality (mmol/kg)Semen 321PRÉ 502KY Jelly 2510ID Glide 3150Elbow Grease 3865Astroglide 6113Gynol II (N9) 1245Wet Platinum NA
  9. 9. How to Make aRectal Microbicide
  10. 10. Phase 1 Studies Safety  General  Mucosal Acceptability Adherence (Efficacy)
  11. 11. Anatomy 101
  12. 12. Rectal Mucosa
  13. 13. A Phase 1 RM Study 0.1% BaselineScreening Enrollment Randomization 0.25% Endoscopy Placebo 2nd 7 single 3rd Single dose Endoscopy Doses EndoscopyAnton et al. PloS ONE 2011
  14. 14. Oral or Topical ARV PrEP? Blood Mucosa OralTopical Concentration of ARV
  15. 15. RMP-02/MTN-006 Safety, PK / PD, acceptability Single 7 Day Open label rectal Rectal Baseline Oral tenofovir tenofovir tenofovir Evaluation (N = 18) (N = 18) (N = 18) 2:1 2:1Anton et al. CROI 2011
  16. 16. Product Acceptability 80 Tenofovir Placebo% of participants 60 40 20 0 Like Discomfort Likelihood of Use
  17. 17. Enough Drug? Concentration of TVF-DP (fmol/mg)Route Oral Rectal (S) Rectal (7D)N Detectable 7/18 10/12 12/12
  18. 18. In Vitro Explant ChallengeEndoscopic biopsies + Virus +/- Drug
  19. 19. Did the Microbicide Work? Oral Dose Single Rectal Dose Multiple Rectal Dose 15000 10000 ViralInfectionIn Rectal 5000Biopsies 0 0 1 2 3 4 Drug Concentration in the Biopsies
  20. 20. MTN-007 7-14 day 7-14 day 2% N-9 interval interval (N=17) 1% TFV Baseline Single 7 day daily N=65 (N=16) Evaluation dose doses HEC (N=16)Screening Endoscopy No Safety/behavioral Treatment assessment (N=16) PI: Ian McGowan
  21. 21. Gastrointestinal SymptomsGI Adverse Events MTN-007 RMP-02/MTN-006in the Tenofovir Arm (N = 16) (N = 12) RG Formulation Original Formulation N %Abdominal pain 6 50%Rectal urgency 5 42%Bloating 5 42%Nausea 4 33%Diarrhea 7 58%Flatulence 3 25%Proctalgia 0 0%Other 5 42%Total 12 100%
  22. 22. Gastrointestinal SymptomsGI Adverse Events MTN-007 RMP-02/MTN-006in the Tenofovir Arm (N = 16) (N = 12) RG Formulation Original Formulation N % N %Abdominal pain 3 16% 6 50%Rectal urgency 0 0% 5 42%Bloating 0 0% 5 42%Nausea 0 0% 4 33%Diarrhea 1 6% 7 58%Flatulence 6 38% 3 25%Proctalgia 1 6% 0 0%Other 4 25% 5 42%Total 9 56% 12 100%
  23. 23. Changes in the Rectal Mucosa Placebo Gel (N = 16) Tenofovir Gel (N = 642)
  24. 24. Other Rectal Microbicide Studies
  25. 25. CHARM Program Combination HIV Antiretroviral Rectal Microbicide Program Development of rectal specific ARV microbicides Humanized mouse model Phase 1 studies  Tenofovir  Maraviroc  Tenofovir & MaravirocIPCP: U19 AI082637
  26. 26. Project GelNICHD R01: Ian McGowan & Alex Carballo-Dieguez
  27. 27. Microbicide Safety and Acceptability in Young Men Stage 1A Stage 1B Stage 2 Screening 3 month acceptability & Phase 1 Tenofovir adherence study with rectal 240 MSM placebo gel safety study Consensual RAI 120 MSM 42 MSM in last month RAI in last 3 months 80% adherence in URAI in last year Stage 1B STI negativeR01 HD059533
  28. 28. Phase 2 Studies
  29. 29. MTN-017 Phase 2 rectal  Endpoints safety study of  Safety tenofovir gel  Adherence N = 186  Self report International sites  Objective  measures United States (4)  Acceptability  Thailand (2)  PK/PD  South Africa (1)  Peru (1)
  30. 30. MTN-017 8 weeks 8 weeks 8 weeks TNF Gel TNF Gel OralBL Daily With sex Truvada TNF Gel TNF Gel OralBL With sex Daily Truvada Oral TNF Gel TNF GelBL Truvada With sex Daily
  31. 31. Phase 2B/3 Studies
  32. 32. Combination PreventionConventional HIV Prevention Package + PrEP SC ± Oral ± Rectal ± Vaginal ± HIV Vaccine
  33. 33. What Will Phase 3 Look Like? Option 1: Tenofovir gel versus placebo + standard prevention package Option 2: Tenofovir gel versus placebo + standard prevention package + permission to use PrEP (HVTN 505) Option 3: Tenofovir gel versus placebo + standard prevention package + Truvada
  34. 34. Social Marketing
  35. 35. Rectal Microbicide Timeline* 2010 2011 2012 2013 2014 2015 2016 2017 2018Phase 1Phase 2Phase 2BReviewAvailableVaginalmicrobicides *An approximation based on tenofovir 1% gel
  36. 36. Summary Rectal microbicides are needed for men and women in the developed and developing world who are at risk of HIV associated with unprotected RAI RM development has moved from Phase 1 to Phase 2 PK/PD models should increase likelihood of success in Phase 2B/3 Planning for an RM effectiveness study needs to start now.
  37. 37. Acknowledgements

×